GR3005447T3 - - Google Patents

Info

Publication number
GR3005447T3
GR3005447T3 GR920400780T GR920400780T GR3005447T3 GR 3005447 T3 GR3005447 T3 GR 3005447T3 GR 920400780 T GR920400780 T GR 920400780T GR 920400780 T GR920400780 T GR 920400780T GR 3005447 T3 GR3005447 T3 GR 3005447T3
Authority
GR
Greece
Prior art keywords
galanthamine
alzheimer
disease
treated
Prior art date
Application number
GR920400780T
Other languages
Greek (el)
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25227312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR3005447(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GR3005447T3 publication Critical patent/GR3005447T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
GR920400780T 1986-01-15 1992-08-20 GR3005447T3 (cg-RX-API-DMAC10.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/819,141 US4663318A (en) 1986-01-15 1986-01-15 Method of treating Alzheimer's disease

Publications (1)

Publication Number Publication Date
GR3005447T3 true GR3005447T3 (cg-RX-API-DMAC10.html) 1993-05-24

Family

ID=25227312

Family Applications (2)

Application Number Title Priority Date Filing Date
GR88300077T GR880300077T1 (en) 1986-01-15 1988-10-21 Galanthamine or analogues thereof for treating alzheimer's disease
GR920400780T GR3005447T3 (cg-RX-API-DMAC10.html) 1986-01-15 1992-08-20

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GR88300077T GR880300077T1 (en) 1986-01-15 1988-10-21 Galanthamine or analogues thereof for treating alzheimer's disease

Country Status (10)

Country Link
US (1) US4663318A (cg-RX-API-DMAC10.html)
EP (1) EP0236684B1 (cg-RX-API-DMAC10.html)
JP (1) JPH08778B2 (cg-RX-API-DMAC10.html)
AT (1) ATE76294T1 (cg-RX-API-DMAC10.html)
AU (1) AU593051B2 (cg-RX-API-DMAC10.html)
DE (3) DE10199020I2 (cg-RX-API-DMAC10.html)
ES (1) ES2000428T3 (cg-RX-API-DMAC10.html)
GR (2) GR880300077T1 (cg-RX-API-DMAC10.html)
LU (1) LU90710I2 (cg-RX-API-DMAC10.html)
NL (1) NL300140I2 (cg-RX-API-DMAC10.html)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150354A (en) 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
AU632458B2 (en) * 1987-05-04 1993-01-07 Bonnie Davis Compounds for the treatment of alzheimer's disease
IT1222395B (it) * 1987-07-30 1990-09-05 Pierrel Spa Composizione farmaceutica per somministrazione intranasale comprendente l'ormone ghrh,un agonista colinergico e/o un sale biliare
US4897388A (en) * 1988-12-20 1990-01-30 Geriatric Research Institute, Inc. Method of treating Alzheimer's disease
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
NZ242744A (en) * 1991-05-14 1997-02-24 Ernir Snorrason Use of a cholinesterase inhibitor (eg a galanthamine derivative) for treating fatigue
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
US5177070A (en) * 1991-11-15 1993-01-05 Ciba-Geigy Corporation Method of treating physiologic male erectile impotence
DE4301783C1 (de) * 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
DE4301782C1 (de) * 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
US6323196B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323195B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6316439B1 (en) 1993-10-15 2001-11-13 Aventis Pharamaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
KR100352212B1 (ko) * 1994-10-21 2003-04-18 자노케미아 파마조이티카 악티엔게젤샤프트 4a,5,9,10,11,12-헥사히드로-6H-벤조푸로[3a,3,2-ef][2]벤즈아제핀유도체의제조방법
US6407229B1 (en) 1994-10-21 2002-06-18 Sanochemia Pharmazeutika Ag Processes for the preparation of derivatives of 4a,5,9,10,11,12-hexahydro-6H-benzofuro-[3a,3,2-ef][2] benzazapine
DE19509663A1 (de) 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
AT402691B (de) * 1996-01-26 1997-07-25 Sanochemia Ltd Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome
AT403803B (de) * 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
AU2004242546B2 (en) * 1998-11-23 2008-05-15 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
EP2311441A1 (en) * 1998-11-23 2011-04-20 Bonnie M. Davis Dosage formulations for acetylcholinesterase inhibitors
DK1140105T3 (da) * 1998-12-24 2004-02-23 Janssen Pharmaceutica Nv Galantaminpræparat med styret frigivelse
US20050063998A1 (en) * 1999-10-26 2005-03-24 Francois Marc Karel Jozef Oral solution containing galantamine and a sweetening agent
AU2000234779B2 (en) * 2000-01-28 2005-11-10 Tricia Grose Herbal supplement for cognitive related impairment due to estrogen loss
US6426097B2 (en) 2000-01-28 2002-07-30 Herbaceuticals Inc. Herbal supplement for cognitive related impairment due to estrogen loss
ATE263171T1 (de) 2000-03-31 2004-04-15 Sanochemia Pharmazeutika Ag Neue derivate und analoga von galanthamin
CA2310990A1 (en) 2000-04-03 2000-10-09 Michael Pontecorvo A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease
CA2310926C (en) 2000-04-03 2002-10-15 Janssen Pharmaceutica N.V. A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
JP4721386B2 (ja) * 2001-07-10 2011-07-13 第一三共株式会社 新規ガランタミン類縁体
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
BRPI0311780B8 (pt) 2002-06-14 2021-05-25 Toyama Chemical Co Ltd composição farmacêutica para melhorar a função cerebral
US20040067934A1 (en) * 2002-10-03 2004-04-08 Parys Wim Louis Julien Use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
WO2004037234A2 (en) * 2002-10-24 2004-05-06 Merz Pharma Gmbh & Co. Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
US20040097484A1 (en) * 2002-11-14 2004-05-20 Marc Cantillion Once a day galantamine pharmaceutical compositions and methods of use
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
US20050004104A1 (en) * 2003-05-30 2005-01-06 Cali Brian M. Methods for the protection of memory and cognition
US20050048543A1 (en) * 2003-07-11 2005-03-03 Jeroen Aerssens CHRNA2 genetic markers associated with galantamine response
AU2004311577A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
ATE374030T1 (de) * 2003-07-25 2007-10-15 Hoffmann La Roche Kombination eines mglur2 antagonists und eines ache inhibitors zur behandlung von akuten und/oder chronischen neurologischen krankheiten
US20050260613A1 (en) * 2003-10-28 2005-11-24 Genaissance Pharmaceuticals LRPAP1 genetic markers associated with galantamine
BG65658B1 (bg) * 2003-11-13 2009-05-29 "Софарма" Ад Комбиниран лекарствен продукт на основата на галантамин
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US7250258B2 (en) * 2003-12-15 2007-07-31 Pgxhealth Llc CDK5 genetic markers associated with galantamine response
EP1763337A2 (en) * 2003-12-31 2007-03-21 Actavis Group HF Immediate, controlled and sustained release formulations of galanthamine
CA2552114A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
KR20060127136A (ko) * 2004-02-19 2006-12-11 노파르티스 아게 콜린에스테라아제 억제제의 혈관성 우울증을 치료하기 위한용도
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
EP1745180A1 (en) * 2004-04-29 2007-01-24 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
US20050267076A1 (en) * 2004-05-14 2005-12-01 Johns Hopkins University Method for improving cognitive function
US20080045500A1 (en) * 2004-07-01 2008-02-21 Eisai R&D Management Co., Ltd. Nerve Regeneration Stimulator
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
US8058291B2 (en) 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
MX2007005137A (es) * 2004-11-23 2007-06-22 Warner Lambert Co Derivados del acido 7-(2h-pyrazol-3-il)-3, 5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de lipidemia.
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
JP2008525439A (ja) * 2004-12-23 2008-07-17 ボイジャー・ファーマシューティカル・コーポレーション アルツハイマー病の治療のための酢酸ロイプロリド及びアセチルコリンエステラーゼインヒビターまたはｎｍｄａレセプターアゴニスト
US20080188510A1 (en) * 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
WO2007014124A2 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
WO2008006099A2 (en) * 2006-07-07 2008-01-10 Myriad Genetics, Inc. Treatment of psychiatric disorders
WO2008051599A2 (en) 2006-10-27 2008-05-02 Medivation Neurology, Inc. Combination therapies for treating alzheimer's disease using i. a. dimebon and dolepezil
US20110201597A1 (en) 2008-03-27 2011-08-18 Chase Thomas N Method and composition for treating alzheimer-type dementia
AU2009229372C1 (en) 2008-03-27 2017-02-02 Chase Pharmaceuticals Corporation Use and composition for treating dementia
MX2012003207A (es) 2009-09-18 2012-05-29 Chase Pharmaceuticals Corp Metodo y composicion para tratar la demencia de tipo alzheimer.
EP2503996A2 (en) 2009-11-26 2012-10-03 USV Limited Controlled release pharmaceutical compositions of galantamine
EA202092673A3 (ru) 2010-02-09 2021-05-31 Дзе Джонс Хопкинс Юниверсити Способы и композиции для улучшения когнитивной функции
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
FR2962335B1 (fr) 2010-07-12 2013-01-18 Cll Pharma Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives
KR20150048888A (ko) 2012-09-05 2015-05-07 체이스 파마슈티칼스 코포레이션 항콜린 신경보호 조성물 및 그 방법
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
BG66818B1 (bg) 2013-03-07 2019-01-31 Berbee Beheer B. V. Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
JP6433482B2 (ja) 2013-03-15 2018-12-05 エージンバイオ， インコーポレイテッド 認知機能を改善するための方法および組成物
TW201540301A (zh) 2013-08-16 2015-11-01 Takeda Gmbh 以ｐｄｅ４抑制劑治療認知損傷
BR112017025031B1 (pt) 2015-05-22 2023-03-21 Agenebio, Inc Composições farmacêuticas de liberação prolongada de levetiracetam

Also Published As

Publication number Publication date
AU6760987A (en) 1987-07-16
EP0236684A2 (en) 1987-09-16
GR880300077T1 (en) 1988-10-21
ATE76294T1 (de) 1992-06-15
DE3779149D1 (de) 1992-06-25
DE10199020I1 (de) 2001-05-23
AU593051B2 (en) 1990-02-01
ES2000428T9 (es) 2013-08-14
NL300140I1 (nl) 2004-02-02
ES2000428T3 (es) 1993-10-01
US4663318A (en) 1987-05-05
EP0236684B1 (en) 1992-05-20
EP0236684A3 (en) 1988-12-14
DE10199020I2 (de) 2004-05-06
DE236684T1 (de) 1988-04-28
LU90710I2 (fr) 2001-03-05
ES2000428A4 (es) 1988-03-01
JPS62215527A (ja) 1987-09-22
JPH08778B2 (ja) 1996-01-10
NL300140I2 (nl) 2004-04-01

Similar Documents

Publication Publication Date Title
GR3005447T3 (cg-RX-API-DMAC10.html)
EP0558100A3 (en) Bipolar transistor
GB9026055D0 (en) Bearing treatment
GB8621869D0 (en) Treatment
PT84294A (en) Novel treatment
KR960003369B1 (en) Transistor arrangement
ZA879505B (en) Flyslag treatment
EP0343879A3 (en) Bipolar transistor
ZA87481B (en) Fabrik treatment agents
EP0333997A3 (en) Bipolar transistor
GB8610314D0 (en) Bipolar transistor
NZ220242A (en) Regulating fertility in cattle by administering epostane
IT8821688A0 (it) Macinacaffe&#39;.
GB8617623D0 (en) Treatment
GB8615669D0 (en) Treatment
CS551586A1 (en) Sposob vyroby bimetalickych suciastok s minialnou medzou pevnosti v tahu oceloveho podkladu 1800 mpa
GB8914964D0 (en) Novel treatment i
GB8616275D0 (en) Treatment
GB8623507D0 (en) Treatment
GB8628935D0 (en) Treatment
GB8629641D0 (en) Treatment
GB8619094D0 (en) Treatment
GB8630486D0 (en) Treatment
GB8619487D0 (en) Treatment
GB8627070D0 (en) Treatment